Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 10/20 | 0.78 |
| ▸ | PRKACG | P22612 | 10/20 | 0.78 |
| ▸ | PRKACB | P22694 | 10/20 | 0.78 |
| ▸ | GSK3B | P49841 | 5/20 | 0.78 |
| ▸ | CDK4 | P11802 | 3/20 | 0.78 |
| ▸ | CCND1 | P24385 | 3/20 | 0.78 |
| ▸ | PRKCA | P17252 | 3/20 | 0.78 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.78 |
| ▸ | CDK1 | P06493 | 3/20 | 0.78 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.78 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.78 |
| ▸ | PIM1 | P11309 | 2/20 | 0.78 |
| ▸ | PRKCB | P05771 | 2/20 | 0.78 |
| ▸ | PRKCH | P24723 | 2/20 | 0.78 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.78 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525501 | 1.00 | PRKD1 (1.00) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL29353099 | 1.00 | PRKD1 (1.00) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL29041083 | 0.96 | PRKD1 (0.92) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL9085119 | 0.95 | PRKD1 (0.90) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL7814801 | 0.94 | PRKD1 (0.88) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL7823817 | 0.93 | PRKD1 (0.87) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL9086159 | 0.93 | PRKD1 (0.87) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL7815373 | 0.91 | PRKD1 (0.84) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL9085659 | 0.89 | PRKD1 (0.81) | PRKD1TDP1PRKACAPRKACGPRKACB | |
| SCHEMBL9083990 | 0.89 | PRKD1 (0.81) | PRKD1TDP1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201173-A1 | SMAD4 Complex Inducers and Uses in Cancer Therapy | UNIV EMORY (US) | 2023-06-29 | — | — | US | claimed |
| US-20120238019-A1 | STEM CELL CULTURE MEDIA FOR MAINTAINING STEMNESS OR INDUCING DIFFERENTIATION OF STEM CELLS | COLLEGE OF MEDICINE POCHON CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-09-20 | — | — | US | claimed |
| EP-0397060-B1 | Maleinimide derivatives and their use as medicines | GOEDECKE AG (DE) | 2001-11-21 | — | — | EP | claimed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | claimed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | claimed |
| US-20260049275-A1 | INDUCED STEM CELLS | UNIV MONASH (AU) | 2026-02-19 | — | — | US | disclosed |
| EP-4678737-A1 | METHOD FOR PRODUCING PRIMED PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-12492372-B2 | Induced stem cells | MONASH UNIVERSITY (AU) | 2025-12-09 | — | — | US | disclosed |
| US-20250290034-A1 | METHOD FOR PRODUCING NAÏVE PLURIPOTENT STEM CELLS | KYOTO UNIVERSITY (JP) | 2025-09-18 | — | — | US | disclosed |
| US-12385008-B2 | Method for producing retinal tissue | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-12 | — | — | US | disclosed |
| EP-4582534-A1 | METHOD FOR PRODUCING NAÏVE PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250145965-A1 | PRODUCTION METHOD FOR INDUCED PLURIPOTENT STEM CELLS | RIKEN (JP) | 2025-05-08 | — | — | US | disclosed |
| WO-2009029678-A1 | PROTEIN KINASE C-δ INHIBITORS THAT PROTECT AGAINST CELLULAR INJURY AND INFLAMMATION AND PROMOTE ASTROCYTE PROLIFERATION | KAI PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008109382-A1 | NUCLEIC ACID COMPOUNDS FOR INHIBITING PKN3 GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008089494-A2 | METHODS OF USE OF EPSILON INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN | KAI PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080103086-A1 | METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE SECRETION OF HMGB1 | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2008-05-01 | — | — | US | disclosed |
| EP-0397060-B1 | Maleinimide derivatives and their use as medicines | GOEDECKE AG (DE) | 2001-11-21 | — | — | EP | disclosed |
| US-5516915-A | Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049275-A1 | INDUCED STEM CELLS | SALL4, SOX18, LEF1 | PRKD1 570/4885TDP1 2968/4885PRKACA 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.